ClinicalTrials.gg
RecruitingNCT07883928GC3114BUpdated Nov 18, 2026

Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

A Phase 2/3 interventional study of vaccination of GC3114B and Vaccination of Efluelda in Influenza A, Influenza B and Influenza Vaccination, sponsored by GC Biopharma Corp. Recruiting at 1 site in South Korea. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by GC Biopharma Corp · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,806
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 16 studies in Influenza, Human by GC Biopharma Corp. — 1 open to participants now, 1 under way, 1 of them phase 3. Influenza, Human · GC Biopharma Corp..

Planned enrollment
Largest of 16
1,806 · median 407
Started
2026
the only one that year
Phase 2/3
Only one
of the 16
Registered
16th of 16
by date

Among the 16 studies in Influenza, Human by GC Biopharma Corp., this one has the largest planned enrollment, is the only one that started in 2026, is the only one in phase 2/3, and was the 16th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 16 studies in Influenza, Human by GC Biopharma Corp. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Influenza, Human by GC Biopharma Corp., or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, active-controlled, parallel-group clinical trial in adults aged 65 years or older. The study will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.

After providing written informed consent, participants will undergo screening to determine whether they are eligible. Eligible participants will be randomly assigned to a study group and receive a single dose of the investigational product on Day 0.

Participants will record solicited adverse events in a subject diary from Day 0 through Day 7. The study site will contact participants by telephone on Day 7 to check on adverse events, concomitant medications, and diary completion. On Day 28, participants will visit the study site for safety follow-up and blood sampling. Participants will be monitored for serious adverse events for 6 months.

03

Conditions studied

  • Influenza A, Influenza B
  • Influenza Vaccination

Browse trials for

Keywords

  • influenza vaccine
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 65 years or older at the time of IP vaccination
  • Subjects who have voluntarily decided to participate in the study after receiving and understanding a detailed explanation of the study and provided written to comply with the precautions

Exclusion criteria

Exclusion Criteria:

  • History of severe reactions after previous influenza vaccination or to eggs or any component of the vaccine (see Section 6.1) (e.g., anaphylaxis)
  • Record of an influenza vaccination within 24 weeks prior to IP vaccination
  • Known or suspected history of impaired immune function, including congenital or acquired immunodeficiency disorders
  • History or family history of Guillain-Barre syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,806 participants (estimated)

Study arms

  • Experimental
    GC3114B

    inactivated, split influenza vaccine

    Biological: vaccination of GC3114B

  • Active comparator
    Efluelda

    Inactivated split influenza vaccine

    Biological: Vaccination of Efluelda

Interventions

  • Biologicalvaccination of GC3114B

    influenza vaccination

  • BiologicalVaccination of Efluelda

    influenza vaccination

06

What researchers measure

Primary outcomes

  1. Evaluation of the immunogenicity of GC3114B

    HI antibody

    Time frame: Day 28 following IP vaccination

Secondary outcomes

  1. Evaluation of the safety of GC3114B

    Solicited AE

    Time frame: Day 7 following IP vaccination

  2. Evaluation of the safety of GC3114B

    Unsolicited AE

    Time frame: Day 28 following IP vaccination

  3. Evaluation the safety of GC3114B

    SAE

    Time frame: 6 months following IP vaccination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2028, 17 months after the start.

Of 11 phase 2/3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 12. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Oct 20, 2026
StartActual
Oct 12, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Aug 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
Korea University Guro Hospital is now Recruiting
Nov 18, 2026
Title
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Nov 18, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    Korea University Guro Hospital is now Recruiting
    Title Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
    + 2 other changes: verification date and date precision
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07883928
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Oct 12, 2026
Primary completion
Mar 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Hayoung Lee
Contact
CD2_GC3114B@gccorp.com
+82-31-260-9369

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion